Ausgabe 5/2015
Inhalt (24 Artikel)
Personalizing chemotherapy dosing using pharmacological methods
Jai N. Patel, Apostolos Papachristos
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial
Robert J. Morgan, Timothy W. Synold, Jeffrey A. Longmate, David I. Quinn, David Gandara, Heinz-Josef Lenz, Christopher Ruel, Bixin Xi, Michael D. Lewis, A. Dimitrios Colevas, James Doroshow, Edward M. Newman
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89)
Vered Shkalim-Zemer, Shifra Ash, Helen Toledano, Yehuda Kollender, Josephine Issakov, Isaac Yaniv, Ian J. Cohen
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors
Kelong Han, Jin Y. Jin, Mathilde Marchand, Stephen Eppler, Nicholas Choong, Stephen P. Hack, Nalin Tikoo, Rene Bruno, Mark Dresser, Luna Musib, Nageshwar R. Budha
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Johanna C. Bendell, Lee S. Rosen, Robert J. Mayer, Jonathan W. Goldman, Jeffrey R. Infante, Fabio Benedetti, Donghu Lin, Hirokazu Mizuguchi, Christopher Zergebel, Manish R. Patel
Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer
Hyo-Sun Lee, Yun-Gyoo Lee, Dong-Hoe Koo, Sukjoong Oh, Heerim Nam, Jae-Uk Song, Seong Yong Lim, Si-young Lim, Seung-Sei Lee
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)
Benoit You, Gilles Salles, Emmanuel Bachy, Olivier Casasnovas, Hervé Tilly, Vincent Ribrag, Catherine Sebban, Emilie Hénin, Jéome Guitton, Michel Tod, Gilles Freyer
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC)
Daniel J. Allendorf, Rodolfo E. Bordoni, Stefan C. Grant, Mansoor N. Saleh, Vishnu B. Reddy, Mary L. Jerome, Pamela M. Dixon, Deborah K. Miley, Karan P. Singh, Francisco Robert
Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients
Ben F. Bulten, Hein J. Verberne, Louise Bellersen, Wim J. G. Oyen, Aida Sabaté-Llobera, Annelies M. C. Mavinkurve-Groothuis, Livia Kapusta, Hanneke W. M. van Laarhoven, Lioe-Fee de Geus-Oei
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
N. Yamazaki, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki, Y. Kiyohara, A. Tsutsumida, K. Namikawa, R. Okuyama, Y. Otsuka, T. Tokudome
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition
Linna Zhang, Kathleen Scorsone, Sarah E. Woodfield, Peter E. Zage
Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients
Haruka Shinke, Satohiro Masuda, Yousuke Togashi, Yasuaki Ikemi, Aiko Ozawa, Tomoko Sato, Young Hak Kim, Michiaki Mishima, Takaharu Ichimura, Joseph V. Bonventre, Kazuo Matsubara
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
N. Yamazaki, Y. Kiyohara, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki, A. Tsutsumida, S. Yoshikawa, R. Okuyama, Y. Ito, T. Tokudome
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Sameh Mikhail, Maryam B. Lustberg, Amy S. Ruppert, Amir Mortazavi, Paul Monk, Barbara Kleiber, Miguel Villalona-Calero, Tanios Bekaii-Saab
Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype
Manu Lopus, Greg Smiyun, Herb Miller, Emin Oroudjev, Leslie Wilson, Mary Ann Jordan
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
Anthony W. Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A. Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Whitney Kirschbrown, Kyle D. Holen, Lee S. Rosen
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters
Zahra Ajgal, Nicolas Chapuis, George Emile, Anatole Cessot, Jean Marie Tigaud, Olivier Huillard, Pascaline Boudou-Rouquette, Michaela Fontenay, Francois Goldwasser, Jerome Alexandre
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
Anthony W. Tolcher, Patricia LoRusso, Jennifer Arzt, Todd A. Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Jeffrey F. Waring, Jianning Yang, Kyle D. Holen, Lee S. Rosen
Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
Antoinette R. Tan, John Sarantopoulos, Lucy Lee, Larisa Reyderman, Yi He, Martin Olivo, Sanjay Goel
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
Hidenori Mizugaki, Noboru Yamamoto, Hiroshi Nokihara, Yutaka Fujiwara, Hidehito Horinouchi, Shintaro Kanda, Satoru Kitazono, Shigehiro Yagishita, Hao Xiong, Jane Qian, Hideyuki Hashiba, Stacie P. Shepherd, Vincent Giranda, Tomohide Tamura
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
Andrew Gabrielson, Anteneh A. Tesfaye, John L. Marshall, Michael J. Pishvaian, Brandon Smaglo, Reena Jha, Karen Dorsch-Vogel, Hongkun Wang, Aiwu Ruth He
Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations
Christian Queckenberg, V. Erlinghagen, B. C. M. Baken, S. H. G. Van Os, M. Wargenau, V. Kubeš, R. Peroutka, V. Novotný, U. Fuhr
Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors
Vijaya L. Damaraju, Michelle Kuzma, Carol E. Cass, Michael B. Sawyer
Erratum to: Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1
Liu Wei, Liu Ying, Yin Chunxia